menu
    • menu

    Company profile for Enlaza Therapeutics

    Pfanstiehl, a global leader in the manufacture of cGMP high purity, low endotoxin, low metals (HPLE-LM)TM injectable grade excipients.

    Virtual Booth

    Contact Supplier

    Global Pharma Healthcare: Setting the global benchmark in quality, innovation, and care

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.

    Virtual Booth

    Contact Supplier

    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Enlaza Therapeutics is pioneering the field of covalent biologics. These novel classes of protein therapeutics deliver more efficacious and safer treatments for patients. The company’s proprietary War-LockTM platform leverages leading synthetic biology technology for site-specific covalent coupling driven by drug binding. Enlaza is building a pipeline of first-in-class covalent biologics.Operator of a biotechnology research ...
    Enlaza Therapeutics is pioneering the field of covalent biologics. These novel classes of protein therapeutics deliver more efficacious and safer treatments for patients. The company’s proprietary War-LockTM platform leverages leading synthetic biology technology for site-specific covalent coupling driven by drug binding. Enlaza is building a pipeline of first-in-class covalent biologics.Operator of a biotechnology research company intended to offer protein therapeutics. The company enables biological drugs that are engineered to become warheads with the capacity to irreversibly lock to disease-related targets.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Enlaza TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    11099 North Torrey Pines Road, Ste 280 La Jolla, California, 92037
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://enlazatx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/enlaza-therapeutics/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Vertex, Enlaza Declare War on Autoimmune Disease in $2B+ Pact
    Vertex, Enlaza Declare War on Autoimmune Disease in $2B+ Pact

    03 Sep 2025

    // BIOSPACE

    https://www.biospace.com/business/vertex-enlaza-declare-war-on-autoimmune-disease-in-potential-2b-pact

    BIOSPACE
    03 Sep 2025
    Share Share
    Enlaza Therapeutics Appoints Jeffrey Leiden, M.D., Ph.D., As Key Advisor
    Enlaza Therapeutics Appoints Jeffrey Leiden, M.D., Ph.D., As Key Advisor

    18 Jun 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240613497600/en

    BUSINESSWIRE
    18 Jun 2024
    Share Share
    Enlaza Therapeutics secures $100m in Series A funding
    Enlaza Therapeutics secures $100m in Series A funding

    01 May 2024

    // PHARMACEUTICAL TECHNOLOGY

    https://www.pharmaceutical-technology.com/news/enlaza-series-a-funding/

    PHARMACEUTICAL TECHNOLOGY
    01 May 2024
    Share Share
    Enlaza gets JP Morgan, Regeneron backing for covalent biologics
    Enlaza gets JP Morgan, Regeneron backing for covalent biologics

    30 Apr 2024

    // Gwendolyn Wu BIOPHARMADIVE

    https://www.biopharmadive.com/news/enlaza-therapeutics-series-a-covalent-biologics/714649/

    Gwendolyn Wu BIOPHARMADIVE
    30 Apr 2024
    Share Share
    Enlaza Raises $100M Series A Led By J.P. Morgan Private Capital
    Enlaza Raises $100M Series A Led By J.P. Morgan Private Capital

    30 Apr 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240430950707/en

    BUSINESSWIRE
    30 Apr 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search